Molecular Insights into EGFR Inhibition by Lapatinib and Emerging HER2 Mutant Kinase Inhibitors
The Journal of Physical Chemistry B · 16.11.2026
DOI: 10.1021/acs.jpcb.6c03843 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Physical Chemistry B, online erschienen am 16.11.2026. Verfasst von Karnati Ganesh Reddy und 1 weiteren Autor:innen. Die Arbeit nennt 90 Literaturangaben. Gefördert von: Ministry of Human Resource Development.
Abstract (Originalsprache)
The epidermal growth factor receptor (EGFR) plays a central role in the progression of multiple cancers, and resistance to tyrosine kinase inhibitors remains a significant therapeutic challenge. In this study, we employ an integrated computational approach combining molecular docking, all-atom molecular dynamics simulations, and the advanced funnel metadynamics (FM) method to investigate the binding mechanisms of the experimentally supported lapatinib-EGFR system and the potential binding behavior of recently approved HER2 mutant inhibitors zongertinib and sevabertinib toward the EGFR kinase domain. Lapatinib exhibits structural stability of the EGFR kinase domain throughout the simulation. The modeled HER2 mutant kinase inhibitors-EGFR complexes also exhibited stable conformations of the kinase domain. Residue-level interaction and binding mode analysis demonstrate that all inhibitors occupy the canonical binding groove and engage key active-site residues. The relative residence times for lapatinib (1.72 ± 0.14 ns) and zongertinib (1.87 ± 0.16 ns) obtained through τRAMD suggest comparable accelerated dissociation times. In contrast, sevabertinib showed a substantially shorter residence time (0.17 ± 0.01 ns), indicating a faster dissociation process and weaker retention within the kinase binding pocket. The absolute binding free energy of lapatinib (−13.7 ± 0.5 kcal mol–1) obtained from FM is in reasonable agreement with the experimental value. Moreover, the binding free energies of zongertinib (−20.0 ± 0.6 kcal mol–1) and sevabertinib (−9.2 ± 0.8 kcal mol–1) follow trends consistent with their relative residence times. Overall, the combined structural and binding-mode analyses suggest that zongertinib may adopt a favorable binding mode within the modeled EGFR complex. These findings provide a computational hypothesis for the potential interaction of zongertinib with EGFR, which requires further experimental validation.
Förderung
- Ministry of Human Resource Development
Zitieren
APA
Reddy, K. G., & Metya, A. K. (2026). Molecular Insights into EGFR Inhibition by Lapatinib and Emerging HER2 Mutant Kinase Inhibitors. The Journal of Physical Chemistry B. https://doi.org/10.1021/acs.jpcb.6c03843
Vancouver
Reddy KG, Metya AK. Molecular Insights into EGFR Inhibition by Lapatinib and Emerging HER2 Mutant Kinase Inhibitors. The Journal of Physical Chemistry B. 2026. doi:10.1021/acs.jpcb.6c03843
BibTeX
@article{Reddy2026,
author = {Reddy, Karnati Ganesh and Metya, Atanu K},
title = {Molecular Insights into EGFR Inhibition by Lapatinib and Emerging HER2 Mutant Kinase Inhibitors},
journal = {The Journal of Physical Chemistry B},
year = {2026},
doi = {10.1021/acs.jpcb.6c03843}
}
EUVIMED